Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Accounts Payables (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Accounts Payables for 4 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 105.33% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 105.33% increase, with the full-year FY2024 number at $1.0 million, up 99.05% from a year prior.
  • Accounts Payables was $1.4 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $905813.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.4 million in Q3 2025 to a low of $271602.0 in Q3 2023.
  • A 4-year average of $809817.7 and a median of $758668.0 in 2022 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 149.49% in 2024; the steepest drop was 39.21% in 2024.
  • 60 Degrees Pharmaceuticals' Accounts Payables stood at $758668.0 in 2022, then tumbled by 33.28% to $506206.0 in 2023, then surged by 99.05% to $1.0 million in 2024, then surged by 38.08% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Accounts Payables are $1.4 million (Q3 2025), $905813.0 (Q2 2025), and $1.2 million (Q1 2025).